# reload+after+2024-01-21 03:46:05.370858
address1§35 Gatehouse Drive, A2
city§Waltham
state§MA
zip§02451
country§United States
phone§781 996 0955
website§https://www.morphictx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
fullTimeEmployees§115
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Bruce N. Rogers Ph.D.', 'age': 54, 'title': 'President & Interim Principal Executive Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 787883, 'exercisedValue': 0, 'unexercisedValue': 4153810}, {'maxAge': 1, 'name': 'Dr. Timothy A. Springer Ph.D.', 'age': 75, 'title': 'Founder, Independent Director & Member of Scientific Advisory Board', 'yearBorn': 1948, 'fiscalYear': 2022, 'totalPay': 40000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marc  Schegerin M.B.A., M.D.', 'age': 47, 'title': 'CFO & COO', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 722375, 'exercisedValue': 0, 'unexercisedValue': 1277625}, {'maxAge': 1, 'name': 'Dr. Praveen P. Tipirneni M.D.', 'age': 55, 'title': 'CEO, MD & Director (Leave of Absence)', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 991327, 'exercisedValue': 0, 'unexercisedValue': 11200504}, {'maxAge': 1, 'name': 'Mr. Robert E. Farrell Jr., CPA', 'age': 58, 'title': 'Senior VP of Finance & Chief Accounting Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Blaise  Lippa Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. William D. DeVaul Esq.', 'age': 52, 'title': 'General Counsel & Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 601440, 'exercisedValue': 4317338, 'unexercisedValue': 4829301}, {'maxAge': 1, 'name': 'Mr. Aaron  Pelta', 'title': 'Senior Vice President of Business & Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Joanne  Gibbons', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.408
priceToSalesTrailing12Months§204.02402
currency§USD
dateShortInterest§1702598400
forwardEps§-3.84
exchange§NGM
quoteType§EQUITY
shortName§Morphic Holding, Inc.
longName§Morphic Holding, Inc.
firstTradeDateEpochUtc§1561642200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§a1e60ff9-744a-3908-a947-e5d2f0a617cc
gmtOffSetMilliseconds§-18000000
targetHighPrice§76.0
targetLowPrice§27.0
targetMeanPrice§55.13
targetMedianPrice§56.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§8
quickRatio§37.572
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
